Press Releases

Mar 19, 2013
Update on Sativex® in Germany Porton Down, UK, 19 March 2013: GW Pharmaceuticals plc (AIM: GWP, “GW”), the specialty pharmaceutical company focused on cannabinoid science, today provides an update on pricing negotiations in Germany for Sativex® being conducted by GW’s licensing partner, Almirall
Feb 19, 2013
Porton Down, UK; February 19 2013: GW Pharmaceuticals plc (AIM:GWP) today announces the appointment of Cabot Brown as a non-executive director with immediate effect. Mr Brown will sit on the Nominations Committee, Audit Committee, as well as the Remuneration Committee.
Oct 12, 2012
Positive New Sativex® Data from Germany Presented at ECTRIMS that results of the MObility ImproVEments with Spasticity in Multiple Sclerosis (MOVE) 2 observational study performed in Germany, with 300 patients, showed that one month’s treatment with Sativex® (THC:CBD) oromucosal spray reduces
Oct 01, 2012
GW Appoints Chris Tovey as Chief Operating Officer London, UK; October 1st 2012: GW Pharmaceuticals plc (AIM: GWP) today announces the appointment, effective today, of Christopher John Tovey to the newly created position of Chief Operating Officer. Chris, aged 47, joins GW having gained a wealth of
Jun 22, 2012
German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German G-BA establishes positive additional benefit of Sativex® in Multiple Sclerosis Spasticity German
May 22, 2012
Porton Down, UK, 22 May 2012: GW Pharmaceuticals plc (AIM: GWP, “GW” or “the Group”), the specialty pharmaceutical company focused on cannabinoid science, announces its interim results for the six months ended 31 March 2012. COMMERCIAL: STRONG PROGRESS Sativex ® in-market sales grow to £5.4m (H1